Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis SA announced that it has filed for a pre-submission meeting request with the European Medicine Agency to discuss filing for conditional Marketing Authorisation in Europe for Sarconeos in the treatment of severe form of COVID-19.

Scroll to Top